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Chemo-enzymatic cascades of enzymes with transition metal catalysts can oﬀer eﬃcient synthetic
strategies, but their development is challenging due to the incompatibility between proteins and
transition metal complexes. Rhodium catalysts can be combined with alcohol dehydrogenases to
regenerate nicotinamide cofactors using formate as the hydride donor. However, their use is limited, due
to binding of the metals to residues on the enzyme surface, leading to mutual enzyme and catalyst
inactivation. In this work, we replaced the zinc from Thermoanaerobacter brockii alcohol dehydrogenase
(TbADH) with Rh(III) catalysts possessing nitrogen donor ligands, by covalent conjugation to the active
site cysteine, to create artiﬁcial metalloenzymes for NADP+ reduction. TbADH was used as protein
scaﬀold for both alcohol synthesis and the recycling of the cofactor, by combination of the chemically
modiﬁed species with the non-modiﬁed recombinant enzyme. Stability studies revealed that the
incorporation of the catalysts into the TbADH pocket provided a shielding environment for the metal
catalyst, resulting in increased stability of both the recycling catalyst and the ADH. The reduction of
a representative ketone using this novel alcohol dehydrogenase–artiﬁcial formate dehydrogenase
cascade yielded better conversions than in the presence of free metal catalyst.1 Introduction
Alcohol dehydrogenases (ADHs) are valuable biocatalytic tools
for the conversion of ketones into chiral alcohols, providing
a sustainable and eﬃcient alternative to chiral catalysts based
on transition metals.1 The main limitation to their practical
application is the requirement of nicotinamide adenine dinu-
cleotide cofactors (NADH or NADPH) as electron donors. The
complexity of these structures, associated with high cost and
reduced stability, precludes their use as stoichiometric
reducing agents. Therefore, the continuous in situ regeneration
of the cofactor is necessary for economically acceptable trans-
formations with isolated enzymes. Current state of the art for
NAD(P)H recycling is the use of a second catalyst to regenerate
the cofactor at the expense of another reducing agent.2 Enzy-
matic recycling systems have been developed, inspired by the
mechanisms of cofactor balance in living cells, but they are not
universally applicable and may suﬀer from incompatibility
between the two enzyme systems and complexity of product
purication.3
Both chemical and electrochemical delivery of reducing
potential have been investigated, as simpler and more robustttingham, University Park, NG7 2RD,
ingham.ac.uk
tion (ESI) available. See DOI:
Laboratory, Department of Chemistry,
Chemistry 2018alternatives to enzymatic methods.2–6 A very promising option
are chemical catalysts based on Rh(III), Ir(III) and to a lesser
extent Ru(II), which use formate as a reducing agent.7–12
Although less active than formate dehydrogenase (turnover
frequency 250 times lower for NADH formation for the state-
of-the-art Rh complex),3,13 they are compatible with high
temperatures and solvents, and avoid the complexity associated
with a second enzyme. Additionally, organometallic complexes
have been shown to recycle the simpler and less expensive
synthetic NAD(P)H mimics.14,15 Sadler and co-workers also re-
ported the formate-driven reduction of NAD+ to NADH catalysed
by Ru(II) arene complexes in living cells, albeit with reduced
activity compared to the complexes in buﬀer.16
The main limitation of these synthetic regeneration catalysts
is the incompatibility of the metal complexes with coordinating
functionalities present in the mixture, such as accessible amine
or thiol groups present in enzymes.17–19 Restricting the access of
the metal species to the nucleophilic residues on the enzyme
surface is required to solve this problem. Attempts to protect the
catalysts by separately immobilising the enzyme and the metal
complex have been shown to increase process stability, and
oﬀered opportunities for catalyst recycling.4,6 On the other
hand, immobilisation of the catalysts resulted in decreased
catalytic activity due to diﬀusion limitations.20
As an alternative to the immobilisation on solid support,
articial metalloenzymes are constructed by encapsulation of
metal-based catalysts inside protein scaﬀolds, thus overcoming
mass transfer limitations by keeping the catalytic moiety andChem. Sci.
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View Article Onlinethe reagents in homogeneous phase. They have been explored
as a synergistic method in catalyst design, by coupling the
selectivity of enzymes with versatile, human-devised, catalytic
functionality, to aﬀord synthetic capabilities greater than the
sum of the parts.21 Articial metalloenzymes have been shown
to facilitate a range of synthetic reaction chemistries, from
reductions of carbon–carbon and carbon–heteroatom bonds, to
oxygen insertion and carbon–carbon bond formation.21–27
The reduction of NAD(P)+ has also been achieved with metal
catalysts incorporated into proteins, either by covalent linking
to papain,28 or by supramolecular insertion using the well-
established biotin–streptavidin system.29 In this context, Ward
and co-workers reported that the protein host also provided
a shielding environment for the metal catalyst against inhibi-
tory species present in solution. This concept of “molecular
compartmentalisation” has been demonstrated by an increased
activity of the protein-bound compared to the free metal
complex, when used in situ with various enzymes dependent on
NAD(P)H or on NAD(P)Hmimics.30–32 Whilst a range of cofactor-
dependent biocatalysts have been employed in conjunction
with articial metalloenzymes, such as ene reductases, glucose
dehydrogenase and 2-hydroxybiphenyl monooxygenase,
a cascade reaction with alcohol dehydrogenases remains to be
developed. This is most likely due to the ketone reduction
activity of the most successful biotinylated Cp*Ir amino-
sulfonamide complexes reported so far, which would interfere
with the ADH activity.33
In most cases, the design of articial metalloenzymes relies
on the availability of a bioconjugation site within the protein
scaﬀold, whilst substrate-binding features are less important in
the design. Yet, substrate binding in an enzyme active site can
lead to exquisite control over the activation pathway, and thus
to promiscuous reactivities, as demonstrated by Hyster and co-
workers who used an NADPH-dependent reductase to catalyse
radical formation and hydrogen atom transfer.34 Zinc-Fig. 1 Reduction of a model ketone using a native–artiﬁcial enzyme ca
a bidentate ligand. The protein is represented in green, and the rhodium
Chem. Sci.dependent alcohol dehydrogenases are well-suited to build
articial enzymes for NAD(P)+ reduction: they contain a metal-
binding site, a hydrophobic substrate-binding pocket able to
accommodate organic ligands, as well as the NAD(P)+ cofactor-
binding pocket.35 In this study, we will present the development
of hybrid catalysts for NADPH regeneration, by using a zinc-
dependent ADH as host for metal complexes with demonstrated
ability to reduce NAD(P)+. In the native ADH reaction, the
reduction of NAD(P)+ takes place by hydride transfer from an
alcohol hydride donor. We reasoned that the replacement of the
alcohol by a metal hydride donor will provide the advantage of
irreversible hydride transfer from formate to the cofactor. We
hypothesise that the use of ADH as the protein scaﬀold for both
alcohol synthesis (natural ADH) and the recycling of the
cofactor (chemically modied ADH) will result in an increased
robustness of a system where both reactions take place in the
same mixture (Fig. 1). To test this hypothesis, the potential of
the protein to prevent metal inactivation will be studied and the
new articial metalloenzymes will be compared with non-
enzymatic cofactor regeneration catalysts in a synthetic
cascade.2 Results and discussion
2.1 Design and preparation of alcohol dehydrogenase
mutants
ADH from the thermophilic species Thermoanaerobacter brockii
(TbADH) was selected for bioconjugation to a metal complex
catalyst. TbADH is a Zn-dependent bacterial ADH with
a homotetrameric structure, in which the catalytic Zn is bound
by residues C37, H59 and D150.36 Its distinguishing feature
compared to other medium-chain Zn-dependent ADHs is the
absence of a second, structural Zn-binding site. Wild-type
TbADH reduces small aliphatic ketones with high enantiose-
lectivity.37,38Of particular interest is its NADP+ specicity, as wellscade with the same alcohol dehydrogenase scaﬀold. L–L represents
complex is represented in red.
This journal is © The Royal Society of Chemistry 2018
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View Article Onlineas its stability at relatively high temperatures (up to 65–86 C)39
and in the presence of organic solvents.37,40 It was reasoned that
its robustness would facilitate the introduction of organic
ligands within the structure. Covalent anchoring to cysteine was
selected as the method for the bioconjugation of metal cata-
lysts. TbADH contains four cysteine residues per monomer
(Fig. 2A). Two of these have already been covalently labelled
with iodoacetic acid: C203 in the NADP+ binding pocket and
C37 in the Zn-binding site, which could be readily modied in
the absence of catalytic Zn. Previous work also showed that
C203 could be mutated to serine without loss in enzyme
activity.41
WT TbADH was overexpressed in E. coli and puried by
aﬃnity chromatography. The specic activity of this recombi-
nant enzyme was comparable to the native enzyme.39 The
accessibility of the cysteine residues and their reactivity towards
5,50-dithio-bis(2-nitrobenzoic acid) (DTNB) was assessed by
Ellman's assay, which indicated the availability of one thiol per
enzyme monomer in WT TbADH, presumably C203 according
to the structure and previous evidence.41 The triple mutant
C203S-C283A-C295A (hereaer TbADH 3M), obtained by site-
directed mutagenesis, was expressed and puried, showing
similar specic activities compared to WT TbADH (Fig. 2B),
thus suggesting that removal of these thiol groups does not
signicantly alter the native protein structure. This mutant
showed no free thiol content, indicating that C37 was not
available for modication in the presence of zinc. Zinc removal
was achieved by further mutation of the Zn-coordinating resi-
dues to smaller alanine side chains. As expected and conrmed
by ICP-MS analysis, double mutant H59A-D150A contained no
zinc and its reaction with the Ellman's reagent showed the
availability of 1.6 free thiols per monomer for covalent modi-
cation. Thus, a working TbADH scaﬀold containing the ve
mutations H59A-D150A-C203S-C283A-C295A (hereaer TbADH
5M) was prepared, devoid of zinc and containing C37 as the only
reactive free thiol (Fig. 2B). It was hypothesized that a metal
complex attached to C37 would t within the Zn cavity, and in
proximity of the nicotinamide C4 redox site.Fig. 2 (A) Crystal structure of TbADH complexed to NADP+ (pdb 1YKF).
and D150 are highlighted in green and the catalytic zinc ion is shown as a
molecules into the active site. Absolute values for WT TbADHwere as follo
U ¼ mmol min1): 74  7 U mg1; free thiols: 0.98  0.003 per monom
This journal is © The Royal Society of Chemistry 20182.2 Bioconjugation of metal complexes to TbADH
For this study, rhodium catalysts of the type
[Cp*RhIII(N^N)(H2O)]
2+ were selected, which were previously
shown to recycle NAD(P)H with formate as the hydride donor
(N^N ¼ chelate nitrogen donor ligands).7,9 Bipyridine and
phenanthroline ligands containing a bromide functionality
(Scheme 1), and their corresponding metal complexes
[Cp*Rh(Br-L1)Cl]Cl and [Cp*Rh(Br-L2)Cl]Cl, were prepared
according to published procedures (see ESI†). Bromide was
chosen as the alkylating functionality, because this allowed the
design of the shortest possible anchor between the protein and
the metal complex.
The bioconjugation of brominated ligands to TbADH was
assessed by ESI-MS. Labelling of TbADH 5M with Br-L2, con-
taining the bromo acetamide anchor, occurred readily at pH 7,
yielding exclusively the mono-labelled protein. The modica-
tion with Br-L1, bearing an alkyl bromide functionality,
required an increased pH of 8 to achieve more than 50% yield,
and also resulted in unselective modication at a second site
(see ESI†). Free thiols depletion aer conjugation was assayed
by the Ellman's assay and was in good agreement with the
residual amount of free 5M observed by ESI-MS.
When the corresponding rhodium complexes were used, the
alkylation at pH 7 was more specic than at pH 8 or 9,
presumably because of unspecic rhodium binding to depro-
tonated surface residues at the higher pH. The optimum
conditions for the formation of the mono-labelled proteins asCysteine residues are highlighted in magenta, active site residues H59
grey sphere; (B) engineering of TbADH for the covalent binding of small
ws: speciﬁc activity (2-butanol oxidation coupled to NADP+ reduction,
er; Zn content: 0.64  0.02 atoms per monomer.
Scheme 1 Chelate nitrogen donor ligands used in this study.
Chem. Sci.
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View Article Onlinethe major compounds were obtained by incubating TbADH 5M
with 4 equivalents of the metal complex in 100 mM Tris–HCl
buﬀer at pH 7, for 1 h at room temperature. The proteins were
subsequently puried by removing the excess labelling agent on
PD-10 desalting columns. Using this procedure, [Cp*Rh(5M-
C37L1)]2+ was obtained as a mixture with non-labelled 5M,
while [Cp*Rh(5M-C37L2)]2+ was obtained as a mixture with the
di-labelled protein (Fig. 3A). Additionally, MALDI-TOF analysis
of the peptides obtained aer protein digestion with chymo-
trypsin conrmed the covalent labelling at C37 (see ESI†).
Protein concentration was determined by Bradford assay.
Labelled and unlabelled protein samples of the same concen-
trations also showed similar SDS-PAGE band intensities, thus
excluding interference of the metal complex with the assay.
Inductively coupled plasma mass spectrometry (ICP-MS) anal-
ysis showed an average Rh : protein molar ratio of 0.5 : 1 in
both cases. In subsequent experiments, unlabelled protein
concentration was determined by Bradford, whilst labelled
protein concentration was determined from the Rh ICP-MS
analysis.
Characterisation of the labelled proteins by UV-Vis spec-
troscopy indicated the presence of the Rh complex in both
protein samples. The UV-Vis spectrum of [Cp*Rh(5M-C37L1)]2+
showed an absorption band at 323 nm, which could not be
observed in the non-labelled 5Mmutant and was very similar to
the absorption of free [Cp*Rh(Br-L1)]2+. Similarly, an increase in
absorbance compared to 5M was observed for the bio-
conjugated [Cp*Rh(5M-C37L2)]2+ above 300 nm, indicating the
presence of the rhodium–phenanthroline complex (Fig. 3B).
The characteristic absorbance was very similar for the free andFig. 3 Characterisation of covalently labelled TbADH variants, [Cp*Rh
trometry and (B) UV-Vis spectroscopy. UV-Vis analysis was performed
(determined by Bradford assay for the proteins, and by weight for the fr
Chem. Sci.the bioconjugated metal complexes, indicating a similar
primary coordination sphere around the rhodium centre.
To assess non-covalent binding of the catalysts outside the
active site, the zinc-containing TbADH 3M mutant was treated
with the non-brominated Rh catalysts [Cp*Rh(H-L1)Cl]Cl and
[Cp*Rh(H-L2)Cl]Cl. Binding of 0.5 equiv. of rhodium to the
protein was still observed by ICP-MS, although at a diﬀerent site
from C37, as indicated by the almost completely retained
ketone reduction activity of the 3M mutant (data not shown).
This suggested that di-labelling of the protein was due to
rhodium coordination, rather than covalent modication of
residues other than cysteines. Purication by ultraltration,
extensive dialysis or by passing through desalting columns
could not remove the Rh complex, suggesting its strong binding
to the protein. Literature has already reported the binding of up
to 4 equivalents of [Cp*Rh(bipy)(H2O)]
2+ to the thermostable
TADH, potentially to surface histidine and cysteine residues,
without inuencing the catalytic activity of the enzyme.17 Here,
we observed a similar propensity of TbADH to unspecically
bind rhodium complexes. Given that formation of a single
TbADH species covalently bound to one rhodium complex
could not be achieved, we proceeded with the evaluation of the
mixture characterised above.2.3 Formate dehydrogenase activity of articial
metalloenzymes
The ability of the new articial metalloenzymes to reduce
NADP+ using formate as the hydride source was evaluated next,
by following the increase of absorbance at 340 nm, due to the
formation of NADPH (Table 1). Interestingly, a lag phase could(5M-C37L1)]2+ and [Cp*Rh(5M-C37L2)]2+ by (A) ESI-TOF mass spec-
in sodium phosphate buﬀer (100 mM, pH 7), at 10 mM concentration
ee rhodium complexes).
This journal is © The Royal Society of Chemistry 2018
Table 1 Reduction of NADP+ by Cp*Rh complexes in the presence of
formatea
Entry Catalyst Substrate TOFRh (h
1)
1 [Cp*Rh(Br-L1)Cl]Cl NADP+ 248
2 [Cp*Rh(Br-L2)Cl]Cl NADP+ 207
3 [Cp*Rh(5M-C37L1)]2+ NADP+ 59
4 [Cp*Rh(5M-C37L2)]2+ NADP+ 74
5 [Cp*Rh(5M-C37L1)]2+ NAD+ 36
a Catalysis conditions: NAD(P)+ (0.15 mM), sodium formate (500 mM),
Rh catalyst (12.5 mM with articial metalloenzymes; 25 mM with free
catalyst) in buﬀer (sodium phosphate, 100 mM, pH 7) at 50 C. The
reduction rate was measured by monitoring the absorbance at 340 nm.
Edge Article Chemical Science
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View Article Onlinebe observed for about 20–30 seconds at the beginning of the
reactions, during which the enzyme activity was negligible, aer
which time the reaction started (see ESI†). This might be due to
the shielding eﬀect of the protein matrix, slowing down the
initial attachment of either formate or NADP+ to the catalyst.
The turnover frequency (TOF) at 50 C was calculated from the
reaction rate measured during linear absorbance increase. TOF
was dened as the quantity of NADPH formed per unit of time
(calculated using 3340 ¼ 6220 M1 cm1), and divided by the
quantity of the rhodium catalyst (determined by ICP-MS).
The activity of the brominated free catalysts [Cp*Rh(Br-L1)
Cl]Cl and [Cp*Rh(Br-L2)Cl]Cl was similar to previous literature
results (entries 1–2).7,13 When covalently anchored to TbADH,
the rhodium catalysts were less active than in their free form
(entries 3–4), however their activities were comparable with
previously published articial metalloenzymes for NAD+
reduction.28,30 Such a decrease in activity between free and
protein-embedded catalysts has previously been observed for
the NADH regeneration with biotinylated Cp*Ir complexesFig. 4 Inactivation of rhodium catalysts by TbADH. (A) Non-conjugated
conjugated [Cp*Rh(H-L2)Cl]Cl; (D) bioconjugated [Cp*Rh(5M-C37L2)]2+.
mM) in sodium phosphate buﬀer (100 mM, pH 7) at 50 C. Catalyst activ
presence of formate (100 mM) at 50 C. In the absence of TbADH after 1 h
 1 h1 for [Cp*Rh(5M-C37L1)]2+; 112  2 h1 for [Cp*Rh(H-L2)Cl]Cl; 38
This journal is © The Royal Society of Chemistry 2018incorporated into streptavidin.30 Some specicity for NADP+ vs.
NAD+ was observed with the bioconjugated Rh–bipyridine
complex (Table 1, entry 5), but not when the phenanthroline
ligand was used. This result does not reect the NADP+-speci-
city of WT TbADH (specic activity is approx. 120 times higher
with NADP+ than with NAD+, see ESI†). This is likely due to the
rhodium hydride in the articial metalloenzyme being more
exposed than the zinc-bound alcoholate catalytic species in the
wild-type enzyme, and possibly rearranging the cofactor
binding.2.4 Compatibility between bioconjugated Rh catalysts and
TbADH
The mutual inactivation between the Rh-based catalysts and
wild-type TbADH was assessed aer incubation at 50 C for 1 h
and for 24 h (Fig. 4). In the presence of 1 equiv. TbADH
(Rh : TbADH molar ratio ¼ 1 : 1), the free catalysts lost most of
their activity aer incubation at 50 C. This is in line with
previously published data by Hollmann and co-workers, who
demonstrated complete inactivation of up to 4 equivalents of
[Cp*Rh(Bipy)(H2O)]
2+ aer incubation for 1 h with TADH from
Thermus ATN1 species, suggesting the presence of four Rh
binding sites within this enzyme.17 In our work, some residual
Rh activity was still observed aer 1 h incubation, suggesting
that the inactivating eﬀect on the rhodium complex was less
signicant with TbADH than with TADH. However, the activity
of the complexes aer incubation with TbADH was far lower
than in the absence of the enzyme.
When the bioconjugated catalysts were incubated with 1
equiv. TbADH, an increased stability was observed compared to
the free complexes, with 42% and 33% residual activity
observed aer 1 h incubation for [Cp*Rh(5M-C37L1)]2+ and[Cp*Rh(H-L1)Cl]Cl; (B) bioconjugated [Cp*Rh(5M-C37L1)]2+; (C) non-
Rhodium catalysts (10 mM) were incubated with 1 equiv. WT TbADH (10
ity was determined by monitoring NADPH formation at 340 nm in the
heating, TOFRh were as follows: 147 1 h1 for [Cp*Rh(H-L1)Cl]Cl; 28
 1 h1 for [Cp*Rh(5M-C37L2)]2+.
Chem. Sci.
Table 2 Reduction of 4-phenyl-2-butanone using TbADH and Rh-
based NADPH regeneration catalystsa
Entry Regeneration catalyst Conversion (%)
1 — 0
2 [Cp*Rh(5M-C37L1)]2+ 67
3 [Cp*Rh(H-L1)Cl]Cl 57
4 [Cp*Rh(5M-C37L2)]2+ 71
5 [Cp*Rh(H-L2)Cl]Cl 58
a Catalysis conditions: 4-phenyl-2-butanone (5 mM), NADP+ (0.5 mM),
sodium formate (500 mM), Rh catalyst (25 mM), WT TbADH (1.5 mM)
in buﬀer (sodium phosphate, 100 mM, pH 7) at 50 C. Conversion
and enantioselectivities were determined aer 24 h by chiral HPLC,
using a CHIRALCEL OD column. Conversion are presented as
averages of triplicate runs, and standard deviations were <1%.
Enantioselectivities were >99% ee in favour of the (S)-enantiomer, in
all cases.
Chemical Science Edge Article
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View Article Online[Cp*Rh(5M-C37L2)]2+, respectively. This observation conrms
that the protein scaﬀold acts as a shielding environment around
the Rh catalysts, protecting these from deactivation by unspe-
cic interactions with residues on the surface of the enzyme.
Higher Rh/TbADH ratios resulted in increased relative activity
of the complexes (see ESI†).
The benecial eﬀect of bioconjugation was even more
prominent in the case of TbADH deactivation by the Rh cata-
lysts. When exposed to 5 equivalents of Rh catalyst for 1 h,
TbADH activity in the reduction direction remained relatively
constant, irrespective of the type of catalyst used. However,
when the incubation time was 24 h, the activity of TbADH
decreased drastically when free Rh catalyst was present, but
remained >80% in the presence of the articial metalloenzymes
(Fig. 5). Previous work by Steckhan and co-workers suggested no
inhibition of TbADH aer incubation with 0.5 mM
[Cp*Rh(bipy)(H2O)]Cl2, however their experiments were per-
formed at 30 C and did not state the enzyme concentration.8
On the other hand, Hollmann and co-workers have previously
shown that inactivation of TADH by the same catalyst occurred
upon incubation with more than 4 equiv. of Rh. Moreover,
inactivation was pH-dependent, with 80% activity being
retained aer 1 h incubation at pH 8 and room temperature,
and only 25% of the TADH activity remaining aer incubation
at pH 6 with 100-fold Rhmolar excess.17 In our hands, increased
inactivation of TbADH by the Rh(III) complex can be observed at
50 C, but can be avoided by physically separating the complex
from the enzyme surface, by encapsulation into the protein.2.5 Cofactor recycling cascades
Encouraged by the benecial eﬀect of bioconjugation on pre-
venting mutual inactivation between TbADH and the Rh
regeneration catalysts, we developed an ADH–hybrid catalyst
cascade for the reduction of 4-phenyl-2-butanone. In thisFig. 5 Eﬀect of the free and bioconjugated rhodium catalysts on 2-
butanone reduction by WT TbADH. WT TbADH (1 mM) was incubated
with the corresponding Rh catalyst (5 mM) in sodium phosphate buﬀer
(100 mM, pH 7). In the absence of the Rh catalyst, the speciﬁc activity
of WT TbADH (2-butanone reduction coupled to NADPH oxidation)
after 1 h heating was 4.95  0.37 U mg1.
Chem. Sci.system, TbADH was used as the same protein scaﬀold for both
ketone reduction and NADPH regeneration driven by formate
(see Fig. 1).
The reduction of 4-phenyl-2-butanone by TbADH was tested
at 50 C for 24 h, using 0.5% (mol) of either free or bio-
conjugated NADPH regeneration catalysts (see Fig. 1). Given the
much lower turnover frequencies of Rh catalysts (0.02 s1)
compared to TbADH (2 s1 for 2-butanone, data not shown),
the amount of TbADH necessary to perform the transformation
should be orders of magnitude lower than the amount of Rh.
However, in line with stability studies, TbADH inactivation
occurred at concentrations <1 mM, which resulted in the use of
an optimised ratio of 25 mM Rh and 1.5 mM WT TbADH. The
extent of inactivation was lower when bioconjugated catalysts
were used (see ESI†). Although the initial activity of the free Rh
catalysts for NADP+ reduction was higher (see Table 1), the
bioconjugated catalysts had better overall performance for the
reduction of the ketone substrate, with 18–20% increase in
conversion being observed (Table 2). This is likely to be due to
the increased stability of both the ketone reduction, and the
NADPH regeneration catalysts present in the same reaction
vessel over 24 h. The enantioselectivity of the reaction was not
aﬀected by the presence of the catalyst, in either free or bio-
conjugated form (>99% ee (S) was obtained in all cases). Ketone
reduction by the articial metalloenzymes was very slow, and
could only be detected at rhodium concentrations much higher
than those used in the regeneration experiments (TOF 0.1–0.2
h1). This is in line with previous reports, where a very low
turnover was observed with the [Cp*Rh(bipy)(H2O)]
2+ catalyst,
compared to enzymatic ketone reduction, under aqueous
conditions at neutral pH.8,423 Experimental
3.1 Bioconjugation of metal complexes to TbADH
The gene encoding for wild-type TbADH bearing an N-terminal
StrepTagII, cloned in the expression vector pET21a, was ob-
tained from Biomatik (Ontario, Canada). Mutagenesis was
performed using the QuikChange Lightning Site-DirectedThis journal is © The Royal Society of Chemistry 2018
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View Article OnlineMutagenesis Kit (Agilent Technologies), following manufac-
turer's instructions. Recombinant overexpression was carried
out in E. coli BL21(DE3). Wild-type TbADH and mutants H59A-
D150A-C203S-C283A-C295A (5M) and C203S-C283A-C295A (3M)
were routinely characterized by SDS-PAGE, enzymatic activity,
protein concentration, ICP-MS to determine metal content and
Ellman assay to determine availability of thiol groups. The wild-
type TbADH sequence, primers used for mutagenesis and
details of protein expression, purication and characterisation
can be found in the ESI.† Ligands Br-L1 and Br-L2, and metal
complexes [Cp*Rh(Br-L1)Cl]Cl and [Cp*Rh(Br-L1)Cl]Cl were
synthesized according to the literature.
Covalent conjugation of complexes [Cp*Rh(Br-L1)Cl]Cl and
[Cp*Rh(Br-L1)Cl]Cl to TbADH 5M was performed in 100 mM
Tris–HCl pH 7, by incubating 4-fold molar excess of the
brominated Rh catalysts with TbADH 5M, for 1 h at room
temperature. Unbound catalyst was removed by desalting
through a PD-10 column (GE Healthcare), followed by concen-
tration by ultraltration with Vivaspin 6 (10 kDa MWCO,
Sartorius). The owthrough was routinely tested for the absence
of catalytic activity and Rh content, thus supporting the absence
of free catalyst in the articial metalloenzyme preparations. UV-
visible absorbance spectra were acquired in 100 mM sodium
phosphate pH 7 with a Cary 8454 spectophotometer (Agilent
Technologies). Rh content was determined by inductively
coupled plasma mass spectrometry (ICP-MS) with a Thermo
Fisher iCAP-Q instrument, aer digestion of the protein in
nitric acid (trace metal grade, Fisher Scientic) as previously
described.43 Mass spectrometry analysis was performed by
electrospray ionisation time-of-ight (ESI-TOF) in a Bruker
Impact II spectrometer. Before analysis, the protein samples
were desalted in pure water, concentrated up to 5 mg mL1
and then mixed with 1 volume of 0.1% formic acid in
acetonitrile.3.2 Formate-driven NAD(P)+ reduction assays
The reduction rate was measured by monitoring the absorbance
at 340 nm (3 ¼ 6220 M1 cm1) with a Shimadzu UV-2600
spectrophotometer, equipped with CPS-100 temperature
controller. Reactions were performed as previously described,7
in 100 mM sodium phosphate, 500 mM sodium formate pH 7 at
50 C. NAD(P)+ concentration was 0.15 mM. Control experi-
ments were carried out in the absence of any catalyst or in the
absence of formate.3.3 Stability assays
Metal concentration was determined by weight (free catalysts)
or by ICP-MS (articial metalloenzyme). Stability tests were
adapted from previously reported mutual inactivation experi-
ments with [Cp*Rh(Bipy)H2O]
2+ and TADH.17 To test the inac-
tivation of the Rh catalyst by TbADH, 10 mM Rh catalyst (non-
brominated complex, or corresponding articial metal-
loenzyme) was incubated with 10 mM TbADH in 100 mM
sodium phosphate pH 7 at 50 C. Samples were taken aer 1 h
or 24 h and the residual activity was assayedThis journal is © The Royal Society of Chemistry 2018spectrophotometrically aer the addition of sodium formate
(100 mM nal concentration) and NADP+ (0.15 mM nal
concentration).
To test the inactivation of TbADH by the Rh catalyst, 1 mM
TbADH was incubated with 5 mM Rh catalyst (non-brominated
catalyst, or corresponding articial metalloenzyme) in 100 mM
sodium phosphate pH 7 at 50 C. Samples were taken aer 1 h
or 24 h and the residual activity was assayed spectrophoto-
metrically aer the addition of 2-butanone (50 mM nal
concentration) and NADPH (0.2 mM nal concentration).3.4 NADPH recycling assays
The assay was performed by adapting previous literature
protocols.8 The reaction mixture (250 mL) contained 4-phenyl-2-
butanone (5 mM), TbADH (1.5 mM), NADP+ (0.5 mM), Rh cata-
lyst (non-brominated catalyst, or corresponding articial met-
alloenzyme, 25 mM) and sodium formate (500 mM), in 100 mM
sodium phosphate pH 7. The mixture was incubated for 24 h at
50 C, then cooled to room temperature, extracted with 1
volume of hexane, dried over Na2SO4 and analysed by chiral
HPLC. The analysis was performed with an Agilent 1220 Innity
equipped with a CHIRALCEL® OD column (4.6 mm  250 mm;
particle size 10 mm). The separation was isocratic at 1mLmin1,
using an isopropanol/hexane mixture 6/94 (v/v). The detection
wavelength was 215 nm. Quantication was achieved by
comparing peak area against standard solutions. Omitting any
of the component from the reaction mixture resulted in no
conversion.Conclusions
Alcohol dehydrogenase was for the rst time used as a protein
host for the design and creation of articial metalloenzymes.
Cp*Rh(III) complexes of bipyridine and phenanthroline bearing
an electrophilic moiety were covalently anchored to thermo-
stable TbADH devoid of active site zinc and containing a single
cysteine in the protein sequence. The resulting conjugated
complexes were shown to catalyse the reduction of NADP+ at 50
C. The mutual inactivation between wild-type TbADH and the
ADH-based articial metalloenzymes was evaluated and showed
an increased stability of both the rhodium catalysts and the
wild-type TbADH, when bioconjugated species were used
instead of free complexes. The ADH-based articial metal-
loenzymes were successfully combined in cofactor recycling
cascades with wild-type TbADH, and aﬀorded higher conver-
sions compared to the free catalysts for the enantioselective
reduction of 4-phenyl-2-butanone. The activity of these articial
metalloenzymes remains 2 orders of magnitude lower than the
activity of recently discovered NADP+-dependent native formate
dehydrogenase systems (0.02 s1 vs. up to 4.8 s1).44 However,
their compatibility with high temperatures and neutral pH
makes them interesting candidates for further development of
regeneration methods with bioconjugated transition metal
complexes. Further research is in progress to optimise the
conjugation site and to improve the binding specicity of
rhodium complexes to TbADH. Additional metals such as RuChem. Sci.
Chemical Science Edge Article
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
A
ug
us
t 2
01
8.
 D
ow
nl
oa
de
d 
on
 9
/3
/2
01
8 
11
:2
9:
46
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineand Ir, as well as diﬀerent ligand architectures will also be
considered, given their reported ability to reduce nicotinamide
cofactors.
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